Cargando…

Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival

BACKGROUND: Different estrogen receptor (ER) and progesterone receptor (PR) expression patterns have important biological and therapeutic implications in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, little is known about hormone receptor (HR)-positiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Y., Wang, Y., He, L., Imani, S., Wen, Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371219/ https://www.ncbi.nlm.nih.gov/pubmed/34392135 http://dx.doi.org/10.1016/j.esmoop.2021.100232

Ejemplares similares

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
por: Duan, Fangfang, et al.
Publicado: (2021)

Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival
por: Peng, Fei, et al.
Publicado: (2021)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

Clinical Nomogram for Predicting Survival Outcomes in Early Mucinous Breast Cancer
por: Fu, Jianfei, et al.
Publicado: (2016)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Use of clinical nomograms for predicting survival outcomes in young women with breast cancer
por: Lin, Hui, et al.
Publicado: (2019)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
por: Deng, G. C., et al.
Publicado: (2021)

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
por: Yap, Y S, et al.
Publicado: (2012)

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer
por: Li, Yilun, et al.
Publicado: (2021)

Establishment and verification of a nomogram for predicting survival in patients with triple-positive breast cancer
por: Wang, Xingguang, et al.
Publicado: (2022)

Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'
por: Altundag, Kadri
Publicado: (2017)

Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer
por: Yang, Yaping, et al.
Publicado: (2019)

Development and validation of nomograms to predict survival in patients with invasive micropapillary carcinoma of the breast
por: Cheng, Yixin, et al.
Publicado: (2023)

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China
por: Lin, Shaoyan, et al.
Publicado: (2020)

Development and Validation of a Nomogram for Predicting Survival in Male Patients With Breast Cancer
por: Chen, Siying, et al.
Publicado: (2019)

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
por: Du, F., et al.
Publicado: (2016)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Predictive biological factors for late survival in patients with HER2-positive breast cancer
por: Kang, Young-Joon, et al.
Publicado: (2023)

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2017)

Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
por: Fujii, Takeo, et al.
Publicado: (2017)

Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer
por: Zhou, Jin, et al.
Publicado: (2021)

A nomogram for predicting the risk of male breast cancer for overall survival
por: Wen, Yahui, et al.
Publicado: (2023)

Development and Validation of a Nomogram for Predicting Survival in Patients with Thyroid Cancer
por: Wen, Qian, et al.
Publicado: (2019)

Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
por: Du, F., et al.
Publicado: (2016)

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
por: Prat, Aleix, et al.
Publicado: (2022)

A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry
por: Guo, Qianqian, et al.
Publicado: (2017)

Development and validation of a nomogram in survival prediction among advanced breast cancer patients
por: Zhao, Jianli, et al.
Publicado: (2020)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer
por: Guo, Lin-Wei, et al.
Publicado: (2018)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
por: Jin, Juan, et al.
Publicado: (2023)

Clinical characteristics and overall survival prognostic nomogram for metaplastic breast cancer
por: Zheng, Caihong, et al.
Publicado: (2023)

Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer
por: Chen, Mao-Shan, et al.
Publicado: (2022)

Development of nomograms for predicting the survival of intestinal-type gastric adenocarcinoma patients after surgery
por: Liu, Chu-Yun, et al.
Publicado: (2023)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Development and validation of a nomogram predicting the overall survival of stage IV breast cancer patients
por: Li, Shunrong, et al.
Publicado: (2017)

Development and validation of novel immune-inflammation-based clinical predictive nomograms in HER2-negative advanced gastric cancer
por: Yang, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f7ugmhlmu9csp1bvg1giu8jbn6